Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03919929 · ClinicalTrials.gov registry record · Phase 2
Treating PCOS With Semaglutide vs Active Lifestyle Intervention
A Phase 2 study of NAFLD and Adolescent Obesity, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT03919929 is a Phase 2 study of NAFLD and Adolescent Obesity that has completed, run by University of Colorado, Denver. The registered enrollment target is 60 participants, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03919929, a Phase 2 study of NAFLD and Adolescent Obesity, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
Conditions Studied
Interventions
- DRUG Semaglutide 3mg and 7mg [Rybelsus]
- OTHER Weight loss diet
Study Locations (1)
Colorado
- University of Colorado Anshutz Medical Campus/Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-05-03 |
| Est. Completion | 2023-10-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03919929
The ClinicalTrials.gov registry entry for NCT03919929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (63% lower). The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with NAFLD appearing as the primary indexed condition, and to 2 interventions - of which Semaglutide 3mg and 7mg [Rybelsus] is the first listed.
NCT03919929 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT03919929 about?
NCT03919929 is a clinical study titled "Treating PCOS With Semaglutide vs Active Lifestyle Intervention". Girls with obesity and polycystic ovarian syndrome will receive either glucagon like peptide-1 receptor agonist therapy or a dietary intervention for 12 weeks to decrease the metabolic syndrome, in particular to lower hepatic fat and improve insulin sensitivity.
What is the current status of trial NCT03919929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2019-05-03. Estimated completion is 2023-10-03.
What conditions does trial NCT03919929 study?
This clinical trial studies the following conditions: NAFLD, Adolescent Obesity, PCOS.
What interventions are being tested in trial NCT03919929?
The interventions under investigation include: Semaglutide 3mg and 7mg [Rybelsus] (DRUG), Weight loss diet (OTHER).
Who is sponsoring clinical trial NCT03919929?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03919929 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
RECRUITING · Phase 2
-
Digoxin In NASH (CODIN)
RECRUITING · Phase 2
-
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.